These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24212514)

  • 1. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
    Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH; Moraes L; Fink MC; Callegaro D; Romano CM; Oliveira AC
    Arq Neuropsiquiatr; 2014 Dec; 72(12):960-5. PubMed ID: 25465776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
    Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
    JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
    Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
    Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
    Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA; Puccio LM; Brydon EW
    J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
    Mazda ME; Brosch JR; Wiens AL; Bonnin JM; Kamer AP; Mattson DH; Snook RJ
    Int J Neurosci; 2013 May; 123(5):353-7. PubMed ID: 23252596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.